Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire-Lakewood HoldingsASBP +2.42%11 Cash-to-Debt is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 0.12. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, Aspire-Lakewood Holdings ranks better than 52.25% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aspire-Lakewood Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aspire-Lakewood Holdingscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Aspire-Lakewood Holdings's Cash-to-Debt or its related term are showing as below:
ASBP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.12 Max: No Debt
Current: 8.12
During the past 4 years, Aspire-Lakewood Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.12.
ASBP's Cash-to-Debt is ranked better than 52.25% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs ASBP: 8.12
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Aspire-Lakewood Holdings Cash-to-Debt Related Terms
Aspire-Lakewood Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Aspire-Lakewood Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire-Lakewood Holdings Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aspire-Lakewood Holdings's Cash-to-Debt falls into.
Aspire-Lakewood Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:
Aspire-Lakewood Holdings had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Aspire-Lakewood Holdings (ASBP) has a Cash-to-Debt of No Debt (1) as of Jun. 2026. This is 733% above median its historical median of 0.12. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #667 out of 1397 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Aspire-Lakewood Holdings' Cash-to-Debt too high?
Aspire-Lakewood Holdings' current Cash-to-Debt of No Debt (1) is 733% above median its 10-year median of 0.12. Based on the distribution chart, Aspire-Lakewood Holdings ranks #667 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' Cash-to-Debt compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #667 out of 1397 companies for Cash-to-Debt. This puts Aspire-Lakewood Holdings in the upper half of its industry. The industry median Cash-to-Debt is 6.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire-Lakewood Holdings's current Cash-to-Debt is No Debt (1), which is 733% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 733% above median its 10-year median of 0.12. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current Cash-to-Debt is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score
Get the complete analysis for ASBP
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
